OncoCyte Corp (NYSE:OCX) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price objective of $10.33 for the company and are predicting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also assigned OncoCyte Corp an industry rank of 81 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research downgraded OncoCyte Corp from a “hold” rating to a “sell” rating in a research report on Thursday, September 15th.
OncoCyte Corp (NYSE:OCX) traded down 3.449% during midday trading on Friday, reaching $4.171. The company had a trading volume of 2,400 shares. The company’s market capitalization is $106.07 million. OncoCyte Corp has a 12-month low of $2.45 and a 12-month high of $10.24. The stock has a 50-day moving average price of $4.51 and a 200 day moving average price of $4.44.
OncoCyte Corp (NYSE:OCX) last issued its quarterly earnings results on Thursday, August 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.01. Equities analysts forecast that OncoCyte Corp will post $0.04 EPS for the current year.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.